SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Soleno Therapeutics, Inc. (SLNO) trades at a trailing P/E of 133.8, forward P/E of 13.3. Trailing earnings yield is 0.75%, forward earnings yield 7.50%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $8.65.
Criteria proven by this page:
- VALUE (53/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 13.3 (down from trailing 133.8) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 0.75% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 7.50% as earnings recover.
- Analyst consensus target $95.25 (+81% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 51/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
53/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SLNO
Valuation Multiples
P/E (TTM)133.8
Forward P/E13.3
PEG Ratio0.01
Forward PEG0.01
P/B Ratio6.21
P/S Ratio14.27
EV/EBITDA93.4
Per Share Data
EPS (TTM)$0.39
Forward EPS (Est.)$3.95
Book Value / Share$8.46
Revenue / Share$3.58
FCF / Share$0.88
Yields & Fair Value
Earnings Yield0.75%
Forward Earnings Yield7.50%
Dividend Yield0.00%
Graham Number$8.65
SharesGrow IV$211.36 (+301.7%)
Analyst Target$95.25 (+81%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-5.2 |
0.10 |
18.28 |
43.29 |
- |
| 2017 |
-5.2 |
0.09 |
3.05 |
-0.05 |
- |
| 2018 |
-13.4 |
0.21 |
5.90 |
0.00 |
- |
| 2019 |
-16.3 |
-0.25 |
33.58 |
0.00 |
- |
| 2020 |
-24.5 |
0.32 |
13.27 |
0.00 |
- |
| 2021 |
-5.3 |
-0.09 |
9.19 |
0.00 |
- |
| 2022 |
-3.5 |
0.07 |
8.03 |
0.00 |
- |
| 2023 |
-17.0 |
0.96 |
4.21 |
0.00 |
- |
| 2024 |
-10.3 |
-0.12 |
7.37 |
0.00 |
- |
| 2025 |
117.9 |
-1.08 |
5.47 |
12.93 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-58.35 |
$1.45M |
$-12.07M |
-831.6% |
| 2017 |
$-26.18 |
$-1.55B |
$-15.67M |
- |
| 2018 |
$-9.54 |
$0.00 |
$-13.34M |
- |
| 2019 |
$-15.78 |
$0.00 |
$-35.92M |
- |
| 2020 |
$-3.68 |
$0.00 |
$-15.38M |
- |
| 2021 |
$-5.56 |
$0.00 |
$-29.56M |
- |
| 2022 |
$-2.42 |
$0.00 |
$-20.32M |
- |
| 2023 |
$-2.36 |
$0.00 |
$-38.99M |
- |
| 2024 |
$-4.38 |
$0.00 |
$-175.85M |
- |
| 2025 |
$0.39 |
$190.41M |
$20.89M |
11% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$3.89 |
$3.33 – $4.89 |
$472.71M |
$453.92M – $498.82M |
11 |
| 2027 |
$6.56 |
$4.00 – $8.28 |
$721.63M |
$676.19M – $801.61M |
9 |
| 2028 |
$9.18 |
$4.72 – $13.23 |
$1B |
$1B – $1B |
7 |
| 2029 |
$12.81 |
$11.43 – $15.01 |
$1.35B |
$1.24B – $1.53B |
2 |
| 2030 |
$16.04 |
$14.31 – $18.79 |
$1.64B |
$1.5B – $1.85B |
5 |
